Intellectual Property Rights in the Global EconomyPeterson Institute, 2000 - 266 lappuses |
No grāmatas satura
1.–5. rezultāts no 31.
4. lappuse
... drugs and agricultural chemicals are widely considered not patentable ; so are biotechnological inventions . Many countries do not protect new plant varieties . Rules protecting trade secrets are absent or weak . Perhaps most ...
... drugs and agricultural chemicals are widely considered not patentable ; so are biotechnological inventions . Many countries do not protect new plant varieties . Rules protecting trade secrets are absent or weak . Perhaps most ...
23. lappuse
... drug producers denied access to the previ- ous test data would be forced to wait for the duration of the exclusivity period before receiving approval unless they also undertook costly test- ing . Moreover , such duplicative testing ...
... drug producers denied access to the previ- ous test data would be forced to wait for the duration of the exclusivity period before receiving approval unless they also undertook costly test- ing . Moreover , such duplicative testing ...
25. lappuse
... drugs and chemicals on patent elsewhere but not yet marketed in these countries is not required , thereby permitting local pharmaceutical firms to continue producing imitations . As partial compensation , however , authorities must ...
... drugs and chemicals on patent elsewhere but not yet marketed in these countries is not required , thereby permitting local pharmaceutical firms to continue producing imitations . As partial compensation , however , authorities must ...
35. lappuse
... drugs in 1993 . Indeed , significant controversies persist over differences in IPRs among developed countries . For example , the United States remained dissatis- fied with aspects of the Japanese patent system until its recent reform ...
... drugs in 1993 . Indeed , significant controversies persist over differences in IPRs among developed countries . For example , the United States remained dissatis- fied with aspects of the Japanese patent system until its recent reform ...
52. lappuse
... drug manufacturers and biotechnology firms in the United States and Europe are in the forefront of programs to strengthen ... drugs , genetic inventions , and seed varieties are precisely the technologies that attract the greatest contro ...
... drug manufacturers and biotechnology firms in the United States and Europe are in the forefront of programs to strengthen ... drugs , genetic inventions , and seed varieties are precisely the technologies that attract the greatest contro ...
Citi izdevumi - Skatīt visu
Intellectual Property Rights in the Global Economy Keith Eugene Maskus Ierobežota priekšskatīšana - 2000 |
Bieži izmantoti vārdi un frāzes
benefits biotechnology Brazil capital chapter China competition policy compulsory licenses considerable consumers copying costs coun developing countries developing economies discussed domestic drugs dynamic effects electronic enforcement European Union evidence example exports firms foreign Fred Bergsten Gary Clyde Hufbauer genetic growth imitation impacts implementation income increase India industrial infringement innovation intellectual property protection Intellectual Property Rights international economic investment IPRS protection ISBN issues Japan John Williamson levels limited market power Maskus Mexico MNEs NAFTA negotiations parallel imports parallel trade patent applications patent laws patent protection patent rights percent pharmaceutical piracy plant varieties potential price discrimination problems programs raise reform regimes regulation requires result reverse engineering rise sectors significant South Korea standards strength of IPRS strengthening stronger IPRs stronger patents Table technical technology transfer tion trade secrets trademarks TRIPS agreement United variable Watal weak IPRs WIPO World
Atsauces uz šo grāmatu
Trade Liberalization and Poverty: A Handbook Neil McCulloch,L. Alan Winters,Xavier Cirera Ierobežota priekšskatīšana - 2001 |
Parental Supervision: The New Paradigm for Foreign Direct Investment and ... Theodore H. Moran Ierobežota priekšskatīšana - 2001 |